To hear about similar clinical trials, please enter your email below
Trial Title:
Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2
NCT ID:
NCT05898009
Condition:
Breast Cancer
Genetic Disease
BRCA2 Mutation
Conditions: Official terms:
Breast Neoplasms
Genetic Diseases, Inborn
Conditions: Keywords:
reunion
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Genetic
Intervention name:
blood sample for BRCA2 mutation detection
Description:
blood sample
Arm group label:
BRCA2 mutation detection
Summary:
In mainland France, breast cancer is the most common cancer in women, with an estimated
incidence of over 58,000 new cases. Even if breast cancer is a cancer with a good
prognosis, it is responsible for more than 12,000 deaths per year (first cause of death
by cancer in women in France).
Breast cancer is a multifactorial disease, which results from the interaction between
environmental, lifestyle, hormonal and genetic risk factors.
In Reunion, more than 400 cases of breast cancer are diagnosed annually. As in mainland
France, it is by far the most common cancer in Reunionese women, and its incidence
continues to increase significantly since the age-standardized incidence rate increased
by 28% between 2007 and 2017 to establish at 64.2/100,000 AP.
Two studies carried out in patients carrying mutations in the breast-ovary predisposition
genes in Reunion, showed that more than 50% of patients carrying BRCA mutation have a
mutation specific to the Reunion population on the BRCA2 gene.
These two studies, which confirm the genetic specificities of Reunion already described
in other pathologies (Mucoviscidosis or Friedreich's Ataxia), suggest that this mutation
could have a significant frequency in patients with breast cancer. Thus, evaluating the
prevalence of this mutation in patients with breast cancer in Réunion would make it
possible to adapt the indications for access to the oncogenetics consultation and the
associated preventive measures
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Domiciled in Reunion at the time of the diagnosis
- Who is diagnosed with a first breast cancer (in situ or invasive) confirmed by
anatomopathological examination during the inclusion period Or Who is diagnosed with
a second breast cancer (in situ or invasive) confirmed by pathological examination
during the inclusion period, contralateral to the first or at least 5 years after
remission of the first
- Having agreed to participate in the study;
- Affiliates or beneficiaries of a social security scheme
Exclusion Criteria:
- Carriers of breast lymphoma,
- Minor patients or patients under guardianship or curatorship
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Mireille IRABE
Address:
City:
Saint-Pierre
Zip:
97432
Country:
France
Status:
Recruiting
Contact:
Last name:
Mireille IRABE
Start date:
October 19, 2023
Completion date:
March 22, 2026
Lead sponsor:
Agency:
Centre Hospitalier Universitaire de la Réunion
Agency class:
Other
Source:
Centre Hospitalier Universitaire de la Réunion
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05898009
